Hair Loss Treatment & Removal in European Union: Market Size, Businesses & Forecast 2026

The Hair Loss Treatment & Removal industry in the European Union encompasses a range of clinical, pharmaceutical, cosmetic, and surgical solutions dedicated to addressing alopecia and unwanted hair. The market is transitioning rapidly from a traditional cosmetic framework to advanced clinical interventions, supported by EU-wide approvals of novel therapies. For instance, the European Medicines Agency (EMA) highlighted critical updates in 2026 regarding the safety protocols and labeling for Janus kinase (JAK) inhibitors like Litfulo (ritlecitinib), which is authorized across the EU to treat severe alopecia areata. Additionally, the sector's operational landscape remains bound to structural st

Industry snapshot

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Hair Loss Treatment & Removal in European Union industry cover?

The industry comprises the manufacturing, distribution, and clinical application of products and procedures designed to mitigate hair loss (alopecia) or facilitate hair removal. This scope spans over-the-counter (OTC) topical applications, prescription pharmaceuticals, laser therapies, and surgical hair transplant procedures. It also overlaps with professional beauty services and clinical dermatology practices across EU member states.

• •Classified under NACE Rev. 2 Code 96.02 ('Hairdressing and other beauty treatment') for non-medical service applications.
• •Includes medical-grade therapies regulated as pharmaceuticals or medical devices under European Union rules.
• •Excludes the manufacturing of wigs, which is officially classified under NACE Code 32.99.

Who operates in the industry and how is it structured?

The European market is highly structured, divided between cosmetic retail channels, clinical dermatology practices, specialized trichology centers, and digital direct-to-consumer (DTC) pharmacies. While everyday consumers often enter the market through retail health and beauty outlets, those with chronic alopecia increasingly rely on formal medical pathways. The physical service segment is characterized by a high volume of small independent clinics, alongside specialized multinational operations.

• •Retail distribution is dominated by health and beauty stores, which maintain the primary physical interface for OTC hair-loss products.
• •E-commerce channels are expanding rapidly, driven by consumer demand for privacy and subscription-based delivery models.
• •Clinical trials for alopecia treatments in the EU are registered and tracked publicly via the EU Clinical Trials Register.

What drives demand in the industry?

The demand for hair loss treatments and removal services in the EU is primarily driven by demographic shifts, such as an aging population, and a rising incidence of autoimmune and androgenetic hair conditions. Furthermore, changing aesthetic preferences and a focus on personal grooming have expanded the consumer demographic, notably among younger demographics and women. Societal awareness and reduced stigma around clinical hair restoration further accelerate uptake.

• •An aging European demographic naturally expands the target market for age-related hair thinning and pattern baldness.
• •Increased clinical trial activity for conditions like alopecia areata highlights a growing focus on targeted therapeutic solutions.
• •The expansion of specialized female hair restoration segments, addressing hormonal, postpartum, and menopausal thinning.

Who are the notable companies in the industry?

The competitive landscape in the EU is highly diverse, featuring major global pharmaceutical companies, cosmetic conglomerates, and specialized biotechnology firms. These entities compete through product innovation, clinical trial pipelines, and retail partnerships. Strong regulatory entry barriers prevent generic or unauthorized products from dominating the high-efficacy segments of the market.

• •Pfizer Inc. holds marketing authorizations in the EU for advanced JAK inhibitors like Litfulo (ritlecitinib), used in treating severe alopecia areata.
• •Johnson & Johnson (via its healthcare divisions) historically drives clinical development for topical formulas, including various formats of Minoxidil.
• •Bristol-Myers Squibb is active in developing pipeline therapies for alopecia, conducting multi-center clinical trials within the EU.
• •Follicum AB has engaged in clinical trials within Europe for novel peptide-based hair growth treatments.

What are the recent trends and outlook?

The industry is moving swiftly toward biotechnology and targeted molecular therapies, shifting the focus from temporary cosmetic concealment to regenerative medicine. At the same time, safety surveillance remains a critical operational trend, with regulators closely monitoring the side-effect profiles of newer systemic treatments. In the hair removal segment, professional-grade home-use laser devices continue to gain market share over traditional salon-based services.

• •The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) updated warnings in July 2026 for JAK inhibitors like Litfulo to ensure safe prescribing practices.
• •A visible rise in clinical trials for JAK inhibitors and other selective immunosuppressants marks a transition toward targeted autoimmune therapies.
• •Increasing integration of digital consultation platforms helps European patients obtain prescription-strength therapies discreetly.

How is the industry regulated?

All hair loss treatments and hair removal systems distributed in the European Union must comply with rigorous safety and efficacy standards. Medicinal products must secure marketing authorization through national competent authorities or the centralized EMA pathway, while cosmetic products must comply with the EU Cosmetics Regulation. Devices used for clinical hair removal or laser therapy require CE marking to prove compliance with EU safety standards.

• •Cosmetic hair formulations are subject to strict ingredient safety assessments under EU Regulation (EC) No 1223/2009.
• •Pharmacovigilance activities, such as Risk Management Plans (RMPs), are legally mandated for companies marketing systemic alopecia drugs like JAK inhibitors in the EU.
• •Clinical trials conducted within the EU must be registered and managed under the centralized Clinical Trials Information System (CTIS).

Government, statistical and trade sources used for this Claight analysis.

• European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) Decisions 2026 ·
• Eurostat NACE Rev. 2 Statistical Classification of Economic Activities ·
• European Union Clinical Trials Register